| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics |
Auckland Cancer Society Research Centre, University of Auckland School of Medicine, Auckland, New Zealand 1000
5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a drug synthesized in this
laboratory that halts tumor blood flow and induces tumor hemorrhagic
necrosis in transplantable murine tumors, is known to induce the
synthesis of antiangiogenic cytokines in vitro. We have
measured the induction of mRNA for modulators of angiogenesis in
vivo and investigated whether DMXAA may also have an additional
antiangiogenic action through the production of these cytokines. The
genes for IFN-
and for interferon-inducible protein 10 (IP-10) were
strongly induced in both spleen and Colon 38 tumor tissue after DMXAA
treatment, whereas that for IFN-
was induced in spleen but not in
tumor. Expression of mRNA for IFN-ß and for the p35 or the p40
subunits of interleukin 12 was not observed in either tissue. Splenic
IP-10 mRNA induction was not a result of IFN-
production
induced with DMXAA because spleen tissue from DMXAA-treated mice that
lacked functional IFN-
receptors expressed similar amounts of
IP-10 mRNA as those from wild-type mice. A single i.p. injection of
DMXAA (20 mg/kg) was sufficient to reduce fibroblast growth
factor-induced endothelial cell invasion of Matrigel implants in
athymic nude mice by nearly 100%. The inactive analogue
8-methylxanthenone-4-acetic acid did not up-regulate the genes for
IP-10 or IFNs and did not inhibit endothelial cell invasion. Antibodies
to IP-10 reversed the inhibition of DMXAA of endothelial cell invasion
by 58%; antibodies to tumor necrosis factor-
, IFN-
, and IFN-
reversed inhibition by 7%, 5%, and 0%, respectively. The data
support the hypothesis that DMXAA, in addition to antivascular effects
mediated by tumor necrosis factor-
, may have an antiangiogenic
effect mediated largely by the induction of IP-10.
This article has been cited by other articles:
![]() |
J. Li, M. B. Jameson, B. C. Baguley, R. Pili, and S. D. Baker Population Pharmacokinetic-Pharmacodynamic Model of the Vascular-Disrupting Agent 5,6-Dimethylxanthenone-4-Acetic Acid in Cancer Patients Clin. Cancer Res., April 1, 2008; 14(7): 2102 - 2110. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. J. Roberts, N. Goutagny, P.-Y. Perera, H. Kato, H. Kumar, T. Kawai, S. Akira, R. Savan, D. van Echo, K. A. Fitzgerald, et al. The chemotherapeutic agent DMXAA potently and specifically activates the TBK1-IRF-3 signaling axis J. Exp. Med., July 9, 2007; 204(7): 1559 - 1569. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. S. Jassar, E. Suzuki, V. Kapoor, J. Sun, M. B. Silverberg, L. Cheung, M. D. Burdick, R. M. Strieter, L.-M. Ching, L. R. Kaiser, et al. Activation of Tumor-Associated Macrophages by the Vascular Disrupting Agent 5,6-Dimethylxanthenone-4-Acetic Acid Induces an Effective CD8+ T-Cell-Mediated Antitumor Immune Response in Murine Models of Lung Cancer and Mesothelioma Cancer Res., December 15, 2005; 65(24): 11752 - 11761. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Seshadri, J. A. Spernyak, R. Mazurchuk, S. H. Camacho, A. R. Oseroff, R. T. Cheney, and D. A. Bellnier Tumor Vascular Response to Photodynamic Therapy and the Antivascular Agent 5,6-Dimethylxanthenone-4-Acetic Acid: Implications for Combination Therapy Clin. Cancer Res., June 1, 2005; 11(11): 4241 - 4250. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. E. Thorpe Vascular Targeting Agents as Cancer Therapeutics Clin. Cancer Res., January 15, 2004; 10(2): 415 - 427. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |